» Articles » PMID: 10702199

Cyclooxygenase 2 Expression in Barrett's Esophagus and Adenocarcinoma: Ex Vivo Induction by Bile Salts and Acid Exposure

Overview
Specialty Gastroenterology
Date 2000 Mar 4
PMID 10702199
Citations 97
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Barrett's esophagus (BE) results from chronic, severe gastroesophageal reflux and predisposes to esophageal adenocarcinoma. Cyclooxygenase (COX)-2 is involved in chronic inflammation and epithelial cell growth. We investigated COX-2 expression in BE and esophageal adenocarcinoma to explore a potential relation between COX-2 expression and metaplasia or carcinogenesis.

Methods: Endoscopic mucosal biopsy specimens of Barrett's intestinal metaplasia (n = 30), Barrett's dysplasia (n = 11), and esophageal adenocarcinoma (n = 5) were compared with normal esophagus (n = 46) and duodenum (n = 46) and analyzed by Western blotting and immunohistochemistry.

Results: Immunoblots revealed constitutive expression of COX-2 in normal esophagus and duodenum. COX-2 protein expression was significantly higher in patients with Barrett's metaplasia, dysplasia, and adenocarcinoma compared with normal squamous esophageal or columnar duodenal epithelia and was heterogenous in different regions of the BE surface. Immunohistochemistry revealed prominent staining in the glands of BE, dysplasia, and adenocarcinoma and faint staining in the basal layers of squamous esophagus and the surface of the duodenum. In response to pulses of acid or bile salts in an ex vivo organ culture system, COX-2 expression increased significantly in BE tissues, and this effect was attenuated by the selective COX-2 inhibitor NS-398.

Conclusions: The results show COX-2 expression in normal esophagus, which increases significantly in BE and esophageal adenocarcinoma. COX-2 is regulated ex vivo by exposure to acid or bile salts.

Citing Articles

A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database.

Zhang Y, Duan D, Tian Q, Wang C, Wei S Front Pharmacol. 2025; 15:1524903.

PMID: 39749203 PMC: 11694325. DOI: 10.3389/fphar.2024.1524903.


Effectiveness of long-term low-dose aspirin in the prevention of gastric cancer after Helicobacter pylori eradication: study design and rationale of Ardabil gastric cancer randomized placebo-controlled prevention trial (AGCPT).

Pourfarzi F, Rashidi M, Yazdanbod A, Nemati A, Dogaheh H, Faghfuri E Trials. 2024; 25(1):617.

PMID: 39300505 PMC: 11412050. DOI: 10.1186/s13063-024-08455-5.


Molecular Biology and Clinical Management of Esophageal Adenocarcinoma.

Li S, Hoefnagel S, Krishnadath K Cancers (Basel). 2023; 15(22).

PMID: 38001670 PMC: 10670638. DOI: 10.3390/cancers15225410.


Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy.

Holmberg D, Mattsson F, Xie S, Ness-Jensen E, El-Serag H, Lagergren J J Gastroenterol. 2022; 57(12):942-951.

PMID: 36258093 PMC: 9663349. DOI: 10.1007/s00535-022-01930-3.


Risk of esophageal adenocarcinoma in patients with Barrett's esophagus using proton pump inhibitors: a systematic review with meta-analysis and sequential trial analysis.

Li L, Cao Z, Zhang C, Pan W Transl Cancer Res. 2022; 10(4):1620-1627.

PMID: 35116488 PMC: 8798809. DOI: 10.21037/tcr-20-3362.